Champions Oncology
CSBR
27 hedge funds and large institutions have $36.7M invested in Champions Oncology in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.68% less ownership
Funds ownership: 41.75% → 41.07% (-0.68%)
10% less funds holding
Funds holding: 30 → 27 (-3)
14% less capital invested
Capital invested by funds: $42.5M → $36.7M (-$5.88M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$416K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$115K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.9K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$9.14K |
| 5 |
BlackRock
New York
|
+$7.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
-$565K |
| 2 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$185K |
| 3 |
Jane Street
New York
|
-$130K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$103K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99.5K |
CSBR Hedge Fund Activity: Q3 2025 in Review
27 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q3 2025, worth a combined $36.7M — down 14% from $42.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CSBR and 2 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $416K. The largest seller was Tocqueville Asset Management, cutting an estimated $565K.
- 27 institutional investors held Champions Oncology (CSBR) as of Q3 2025, down from 30 in Q2 2025.
- Funds reported $36.7M of Champions Oncology stock for Q3 2025, down 14% quarter-over-quarter.
- 2 funds opened new Champions Oncology positions in Q3 2025 and 5 closed out, a net change of -3 holders.
- The largest Champions Oncology buyer in Q3 2025 was Morgan Stanley, an estimated $416K added.
- The largest Champions Oncology seller in Q3 2025 was Tocqueville Asset Management, an estimated $565K sold.
Based on aggregated 13F filings for Q3 2025.